Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 37: 579-581, 1991;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Collazos, J.
Right arrow Articles by Ruibal, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Collazos, J.
Right arrow Articles by Ruibal, A.

Clinical Chemistry, Vol 37, 579-581, Copyright © 1991 by American Association for Clinical Chemistry

Neuron-specific enolase concentrations in serum in benign liver diseases

J Collazos, J Genolla and A Ruibal
Internal Medicine Service, Hospital de Galdacano, Vizcaya, Spain.

Neuron-specific enolase (EC 4.2.1.11; NSE), a glycolytic enzyme produced by neuronal and neuroendocrine cells, is used as a tumor marker of neuroendocrine cancers, especially small-cell lung cancer. We have evaluated the behavior of NSE in nonmalignant liver diseases in 161 patients who underwent a thorough clinical and biochemical evaluation. Nine of the 161 patients (5.6%)--three of the 86 cirrhotic patients (3.5%), and six of the 75 noncirrhotics (8%)--had abnormal concentrations of NSE. Of the numerous clinical and analytical factors considered, none correlated significantly with NSE. The low false- positive rate, similar to or even lower than for other benign diseases, and the absence of association with the numerous characteristics of liver diseases that we studied, support the lack of any substantial metabolism of NSE by the liver. Consequently, the coexistence of a benign liver disease does not limit the usefulness of this enzyme as a tumor marker.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American Association for Clinical Chemistry.